About Us
Our founding team combines talented and accomplished scientists with a wealth of experience in the stem cells and diabetes field, with a strong business and commercialization team. Together, we are committed to translating stem cell technologies into therapeutic applications.
Our goal is to develop high quality, stem cell-based regenerative therapeutic solutions for diabetes. Our core technology was developed at the Agency for Science, Technology and Research (A*STAR) in Singapore.
We run our very own state-of-the-art laboratory facility with both R&D and cell manufacturing capabilities, in the heart of Singapore.
Our Leadership Team
Sci & Ops
Dr. Koh Ye Xin
Technical Operations
Resilind Chew
Zainab Yasin
Lim Kah Meng, PhD
Founder, Chief Executive Officer
Dr Lim Kah Meng has dedicated a large part of his research focus on molecular biomedicine. For more than 20 years, he fervently pursued his scientific interests on bioactive molecules that govern and regulate cellular pathways leading to cellular homeostasis and wellbeing. Being credited as the “Father of Molecular Edible Birds Nests”, Dr Lim has filed multiple patents on the extraction processes for the bioactive molecules including immunological active bio-molecules from edible bird nests.
Dr. Lim is also known in this region to be the “Father of Molecular Placenta” where he has successfully developed highly popular products for the commercial world based on placental stem cell extracts.
He has since diversified into stem cell research including products or platforms based on induced pluripotent stem cells for personalized aesthetic and therapeutic for acute illnesses such as diabetes, psoriasis and dementia. Dr. Lim has also published a paper documenting successful clinical cases for 9 cancer patients in Singapore using high done intravenous vitamin C.
On biologics research, Dr Lim has at least a few years of precious experience; working with leading global biologics experts both at Agency for Science, Technology and Research (A*STAR) [Singapore] as well as at University of Minnesota [USA].
Dr Lim is also deep into biomedical research for neuroscience. He has filed for at least 5 patents related to cannabinoids, specifically on medical cannabis but not exclusive to just neurological functions, optimizing bioactive compounds, Dr. Lim’s most recent research is in successfully using micro RNAs as the next generation diagnostic markers for most cancer and chronic diseases detection. Dr Lim was also the recipient for the Singapore award of the 10 outstanding young persons of the world in 2012.
Dr. Lim joined the Singapore PainCare Holdings Ltd as an independent Non-Executive Director in March 2021 and at the same time, serves as an Honorary Advisor of the World LIN Chamber of Commerce, Singapore.